Drug intelligence / Profile preview

Gepferon

Development stage
Unknown
Lead developer
OTCPharm
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Rectal, Topical
01

Overview

Gepferon is a combination pharmaceutical product developed and marketed by OTCPharm (formerly part of Pharmstandard) for the local treatment of proctological disorders, such as internal and external hemorrhoids and anal fissures. The formulation combines three active components: recombinant human interferon alfa-2b, heparin sodium, and benzocaine. Interferon alfa-2b provides immunomodulatory, anti-inflammatory, and antiviral effects by activating specific cell receptors. Heparin sodium acts as a local anticoagulant that binds to antithrombin III to inhibit thrombus formation, reduce edema, and promote tissue regeneration. Benzocaine serves as a local anesthetic that provides rapid symptomatic relief from pain and itching by blocking voltage-gated sodium channels. It is typically administered as a rectal suppository or topical ointment.

Brand names
GepferonГепферон
02

Targets

IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)ATIII (Antithrombin III)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Gepferon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gepferon.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call